CorMedix Inc.

Welcome to the Corps Medics First Quarter 2026 Earnings and Corporate Update Conference Call. Today's conference call is being recorded. There will be a question and answer session at the end of today's presentation and instructions on how to ask a question will be given at that time. At this time, I would like to turn the conference call over to Dan Ferry from LifeSci Advisors. Please go ahead.

Good morning and welcome to the Corps Medics First Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Tedisco, Chairman and Chief Executive Officer of Corps Medics. And he is joined by Liz Hurlburt, EVP and Chief Operating Officer, and Susan Blum, EVP and Chief Financial Officer. In addition, Seth Zelnick-Coffin, EVP and Chief Legal and Compliance Officer and Corporate Secretary, Mike Seckler, EVP and Chief Commercial Officer, and Dr. Matt David, EVP and Chief Business Officer, are also on the line and will be available during the Q&A session. Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meeting set forth in the Private Securities Litigation Reform Act of 1995. These statements are statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about the company's prospects and future financial position. Actual results may differ materially from the estimates and projections on which these statements are based due to a variety of important factors, including the risks and uncertainties described in greater detail in CoreMedix filings with the SEC, which are available free of charge at the SEC's website or upon request from CoreMedix. CoreMedix may not actually achieve the goals or plans described in these forward-looking statements, and investors should not place undue reliance on these statements. CoreMedix does not intend to update these forward-looking statements except as required by law. During this call, the company will discuss certain non-GAAP measures of its performance. GAAP to non-GAAP financial reconciliations and supplemental financial information are provided in Corematic's earnings release in the current report on Form 8-K filed with the SEC. This information is also available on the Investor Relations section of Corematic's website. At this time, it is now my pleasure to turn the call over to Joe Tedisco, Chairman and Chief Executive Officer of CoreMedix. Joe, please go ahead.

Thanks, Dan. Good morning, everyone, and thank you for joining us on this call. CoreMedix is entering 2026 with strong momentum across our core priorities, delivering durable defend-cash utilization growth, advancing high-value pipeline opportunities, and driving meaningful profitability and cash generation. These elements together form the foundation of our long-term value creation strategy. We announced this morning first quarter net revenue of $127.4 million, significantly above street consensus, and adjusted EBITDA of $70 million. Susan will provide more granular details of first quarter financial results, but I am proud of the team's execution, which led to this fantastic performance. As a result of our Q1 performance, as well as other market intelligence, we are increasing our full-year financial guidance for net revenue from the previously announced range of $300 to $320 million to a revised range of $325 to $345 million. The increase in guidance reflects strong first quarter execution and continued confidence in underlying demand trends, while incorporating expected variability into FinCAS sales in the second half of 2026 as we transition through reimbursement dynamics. We're also raising our full year adjusted EBITDA guidance from the previous range of $100 to $125 million to a new range of $115 to $135 million. DefendCast variability in the back half of 2026 is the result of the expiration of our initial Tdapa reimbursement and the transition to the post-Tdapa add-on phase of reimbursement by CMS. Based on current CMS calculation methodology, the company expects a significant increase in the post-Tdapa add-on amount in 2027 compared to the second half of 2026, which is expected to produce a higher net selling price per unit in 2027 compared to our current estimates for Q3 and Q4 of this year. Our primary objective for Q3 and Q4 is to maintain or grow existing patient utilization heading into 2027. Based upon our first quarter performance and feedback from existing customers, we are raising our full year to FENCAS guidance from the previously announced $150 to $170 million range to a new range of $175 million to $195 million. This guidance is based on existing customer run rates and does not include potential upside from new customers, or any new volumes that result from potential successful contracting with Medicare Advantage, both of which we are actively working hard to pursue. Despite pending Tdap expiration, we continue to see DefendCath evolving into a standard of care therapy within its target population, supported by strong clinical value and increasing adoption. It's worth noting that our three current largest customers for DefendCath have either recently published or presented information demonstrating the positive clinical impact that DefendCath has had on their patients' infection and or CRBSI-related hospitalization rates, or made similar public comments related to the positive impact DefendCath has had in their clinics. In addition to strong Q1 financial performance, we were also excited to recently announce the preliminary top-line clinical results from the RESPECT study, a Phase III clinical study evaluating Roseo for the prophylaxis of invasive fungal disease in adult immunosuppressed patients undergoing allogeneic bone and marrow transplant. As Liz will explain in more detail, we believe the top line results position Roseo to become an attractive option for clinicians for prophylaxis of IFD. And we will now begin to work together with our global partner to prepare for FDA submission of the SNDA in the second half of this year and plan for a potential commercial launch in 2027. With respect to commercial readiness and as we begin to prepare our commercial infrastructure, for a potential launch of Rizale for prophylaxis, we expect to incur incremental spend in the back half of this year, including the anticipated addition of between 15 to 20 incremental headcount across both commercial and medical. This increase in resources and operating spend is reflected in our full-year cash OpEx guidance of $145 to $160 million. As a reminder, our cash OpEx guidance excludes non-cash charges such as stock-based compensation. I'd now like to turn the call over to our Chief Operating Officer, Liz Hurlburt, to provide an update on clinical activities. Liz, please go ahead.